Michael Frumer
Papers
1
Total Citations
37
H-Index
1
About
Michael Frumer is a leading clinician-scientist in urologic oncology, with a focused expertise in theranostics for high-risk prostate cancer. His most impactful work centers on the pioneering application of 177Lu-PSMA radionuclide therapy in the neoadjuvant setting, a strategy designed to improve outcomes before radical prostatectomy. In his landmark single-arm Phase 1 trial, Frumer demonstrated the safety and feasibility of this targeted radionuclide treatment, achieving 37 citations and establishing a new paradigm for integrating molecular imaging and therapy into surgical management. This contribution is critical for patients with aggressive disease, offering a potential path to better local control and reduced recurrence. Frumer’s research bridges nuclear medicine and surgical oncology, and his work is increasingly cited as a foundational step toward personalized, image-guided preoperative regimens. His achievements highlight a commitment to translating novel radiopharmaceuticals from the lab to the operating room, positioning him as a rising authority in the evolving field of prostate cancer theranostics.
Research Focus
Key Achievements
Top Papers
- 1